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Abstract 
There is an imperious need of redefining placebo effect in contemporary times. The effects of sham medical intervention, 
combined with a careful observation of the natural evolution of a disease, could reveal the true efficiency and impact of active drugs. 
This interest is not driven only by a scientific curiosity, but also by the pragmatic fact that the standard process of approving new 
medicines through supportive clinical trials requires a comparison against placebo. A complete understanding of the placebo effect 
should include both its psychological mechanisms and the underlying neurobiology. In contrast to other type of conditions, 
neurological disorders could provide specific clues in understanding the placebo effect, since the pathogenic mechanisms of different 
diseases might interfere with neuronal circuitry involved in the perception of disease symptoms. However, there are ethical 
considerations dictating the limits of using placebo. This paper reviews recent articles about placebo effect, with an emphasis on its 
importance in several neurological conditions (Parkinson's disease, neuropathic pain, headache, multiple sclerosis, epilepsy), and 
intends to offer new insights on this major topic. 
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Introduction 
The term "placebo", which comes from the Latin 
language and means "I shall please", is medically used to 
designate a biologically inert substance or a sham 
surgical intervention that produces a "placebo effect", 
which is defined as a favorable outcome in the course of a 
disease state. Some authors characterize placebo effect 
as a form of interpersonal healing, distinct from the 
natural evolution of a disease, which is present in some 
degree in all healing encounters [1,2]. The body of 
evidences on placebo effects is currently growing in an 
accelerated fashion, as there are annually thousands of 
publications presenting randomized placebo-controlled 
trials. The spectrum of favorable effects noticed when 
using placebo in neurological conditions includes the relief 
of various types of pain, such as headache and 
neuropathic pain, improvement of manifestations of 
Parkinson's disease, reduction of the seizure frequency in 
epilepsy, alleviation of symptoms in multiple sclerosis, as 
well as a fortunate impact on cognitive and mood 
disorders.  
The recent developments in brain imaging 
enabled a better understanding of the neurobiological 
mechanisms underlying the placebo effects, of which the 
opioid and dopaminergic systems are the most reliably 
documented. Placebo is the gold standard for the 
comparison of a new drug in clinical trials, but its effects 
cannot always be properly isolated by trial design, which 
is a matter of dispute in the scientific community. Ethical 
issues regarding the use of placebo are also a hot topic 
nowadays, and careful attention is recommended in order 
to minimize its effects in the clinical research; however, 
there are many voices that have a positive attitude toward 
using placebo in clinical settings.  
Different reviews of literature have been recently 
performed to investigate the placebo effects in the 
neurological disorders, the psychological aspects 
facilitating placebo, the evidences about its 
neurobiological basis, the current views about using 
placebo in clinical trials and the ethical questions raised 
by its use. 
 
Psychological aspects of placebo effects 
Several psychological mechanisms seem to 
contribute to the appearance, enhancement or duration of 
the placebo effects namely classical conditioning and 
cognitive factors, such as expectation, desire and 
reward[3,4,5] . The most important remains the classical 
conditioning, which has been studied in research trials by 
administering an active drug before giving placebo or by 
reducing pain intensity of a stimulus at the same time a 
placebo is given. Conditioning is actually an ubiquitous 
psychological mechanism, as personal previous long-term 
experiences of a patient will influence the results: doctor-
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patient relationship, the trial site, the aspect of the pill, the 
route and the frequency the treatment is given[6].  
The patient's expectation of clinical improvement 
is also responsible for the onset and tailoring of the 
placebo effects. The importance of expectancy has been 
revealed in studies with a balanced placebo design, which 
can be schematically described as the assignment of 
patients to one of four groups: active treatment group 
where they were told they are given active treatment, 
active treatment group where they were told they are 
given placebo, placebo group where they were told they 
are given active treatment, placebo group where they 
were told they are given placebo. One study with this type 
of design performed in cocaine abusers showed that, for 
the group that received methylphenidate, the brain 
glucose metabolism was higher in those who were told 
they were given methylphenidate than in those who were 
told they were given placebo [6]. 
It is also important that the patient has a sense 
of control over the disease by being actively involved in 
the treatment administration, as this will enhance the odds 
of a favorable effect. Moreover, higher placebo effects 
were elicited when patients were given a firm diagnosis, 
performed diagnostic tests, told that a novel procedure 
would be used and encouraged they would get better[6]. It 
is believed that the placebo effects can be enhanced by 
using verbal suggestions that increase the expectation of 
pain relief and decrease the perceived necessity of pain 
reduction; a careful avoidance of these suggestions can 
decrease the placebo effects[7]. One study showed that 
inducing strong expectation of analgesia before sleep 
could be a method of enhancing the placebo effects[8]. 
Another study found a significant correlation 
between some personality traits, like behavioral drive, 
novelty and fun seeking (which are together described as 
"dopamine related traits"), and the propensity to develop a 
placebo analgesic response[9]. 
The outcome of a disease is indeed influenced 
by the doctor-patient relationship. The doctor's attitude 
triggers some favorable or unfavorable 
neuropsychological mechanisms, which will lead to illness 
alleviation or aggravation, respectively. It is interesting to 
note that the patients have the tendency to report better 
placebo outcomes than the clinicians, as one study on 
facial skin rejuvenation revealed - here the improvements 
were perceived only by the subjects, but not by the 
doctors or the blinded experts[10]. 
 
Neurobiological basis of placebo effects 
The first important step in understanding the 
biological basis of the placebo effect was taken by Levine 
et al in1978, who discovered that the analgesic effect 
obtained by using an inert substance was blocked by 
naloxone, an opioid antagonist. Later, a more detailed 
picture about the involvement of opioid system came into 
shape and further arguments were gathered. For 
instance, an enhancement of placebo-induced analgesia 
was obtained by using proglumide, an antagonist of 
cholecystokinin that acts on the opioid system[11]. 
Today a consensus was reached that the 
endogenous opioid system, by the activation of its µ-
opioid receptors, is the main mediator of the placebo 
effects in various types of pain, as shown by the 
measurement of the blood flow by using functional 
magnetic resonance imaging (fMRI) and positron 
emission tomography (PET) with µ-opioid receptor 
selective radiotracer 11Ccarfentanil.  During placebo-
induced analgesia, a reduction in the activation of pain-
sensitive brain areas, such as rostral anterior cingulate 
cortex, prefrontal cortex, insula, thalamus, amygdala, 
nucleus accumbens and periaqueductal gray matter was 
noted[12,13,14].  More detailed PET investigations of 
placebo analgesia found the following involved territories: 
rostral anterior cingulate, orbitofrontal and dorsolateral 
prefrontal cortex, anterior and posterior insula, nucleus 
accumbens, amygdala, thalamus, hypothalamus, 
periaqueductal grey matter, dorsal raphe and cuneiformis 
nuclei [15,16].  
In one study, naloxone was used to decrease 
placebo analgesia by using fMRI. The CNS structures 
involved in this process were revealed as being rostral 
anterior cingulate cortex, periaqueductal gray matter, 
hypothalamus and rostral ventromedial medulla [17]. 
Placebo effect is mediated not only at the supra-spinal 
level, but also in the spinal cord [18]; this finding was 
documented in one study that used fMRI to bring direct 
evidence that, when placebo is used, pain-related activity 
is also decreased in the spinal cord [19]. However, the 
CNS activations induced by placebo analgesia and by 
opioids are only partially superposable, the amplitude of 
activation being higher for the opioid substances [6].  
Placebo analgesia is mediated not only by the 
opioid system, but also by other pathways. It is thought 
that expectation uses the opioid system to induce placebo 
analgesia, but the conditioning may use different 
biochemical systems, according to the drug initially 
administered. When an opioid substance is used for 
conditioning, placebo analgesia occurs via opioid system, 
and can be blocked by naloxone; when another type of 
drug is used, for instance ketorolac, another system 
mediates placebo analgesia, and therefore analgesia 
cannot be antagonized by naloxone [20]. 
A dichotomy was established between the 
transitory and sustained analgesic effects of placebo, and 
it was shown, while using fMRI, that the effects with 
different temporal profiles have distinct CNS origins. The 
transitory component of placebo analgesia is managed by 
cognitive cerebral areas, like language centers in the 
dominant hemisphere and executive functioning centers 
in the non-dominant hemisphere. The sustained 
component of placebo analgesia involves emotional 
areas, located in temporal and parahippocampal cortices 
[21].  
  The activation of dopaminergic system when 
giving placebo has been documented by using PET with 
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the D2/D3 receptor-labeling radiotracer 11Craclopride. One 
study performed on healthy subjects proved that 
intravenous placebo induced dopamine release at the 
basal ganglia level [22]. In patients with Parkinson's 
disease, placebo administration produces dopamine 
release in both dorsal and ventral striatum, as well as in 
the limbic system. By providing dopamine at the dorsal 
striatum level, the alleviation of motor symptoms in 
Parkinson's disease appears as a logical consequence. 
But the activation of ventral striatum and nucleus 
accumbens denotes the implication of the dopamine-
mediated reward system, mechanism that might be 
responsible for part of the placebo effects not only in 
Parkinson's disease, but also in other medical disorders 
[23,24,25]. The degree of dopaminergic activation seems 
very important at the level of nucleus accumbens, this 
being correlated with a subject's expectation of analgesia, 
actualization of this expectancy during the trial and 
amplitude of analgesia [16]. The dopaminergic system is 
thought to be the mediator involved in the placebo effect 
on neuroimmunomodulation as well [26].  
The serotoninergic system seems involved in the 
placebo effects observed in depressive patients, as one 
study that used PET to compare the changes in brain 
glucose metabolism induced by placebo versus 
fluoxetine, showed. During placebo administration, the 
metabolic rate was increased in the prefrontal, anterior 
and posterior cingulate, premotor, posterior insula, 
parietal cortex and decreased in subgenual cingulate, 
parahippocampus and thalamus; similar changes were 
found during fluoxetine treatment. However, changes in 
additional subcortical and limbic areas were seen only 
with fluoxetine, and these are thought to be responsible 
for the sustainability of treatment effects [27]. 
One study investigated the placebo effects on 
EEG recordings, and found that placebo induced a 
decreased P2 amplitude and an increased N2 amplitude, 
with the focus in the proximity of the posterior cingulate. 
Several studies have shown that P2 and N2 are linked to 
visual emotional stimuli, so their variation in amplitude 
corresponds to an emotional mechanism of the placebo 
effect[28].  
The placebo effect has also been studied in 
animals; for instance, one study performed in mice offered 
proofs of the existence of opioid, naloxone reversible, and 
non-opioid, naloxone non-reversible, components of 
placebo analgesia [29]. 
 
Neurological disorders and placebo effects 
Parkinson's disease 
Clinical trials investigating antiparkinsonian 
drugs, deep brain stimulation or transplantation of fetal 
dopaminergic neurons versus placebo, revealed a 
significant improvement of motor function in the placebo 
arms. When a strict assessment of placebo-associated 
improvement was undertaken, by using the Unified 
Parkinson's Disease Rating Scale (UPDRS) motor scale, 
the placebo response rates (improvement in the UPDRS 
motor score of at least 50% or reduction by at least two 
points on two different UPDRS items at one visit), were 
found to be of approximately 16% across multiple studies. 
The placebo response was more pronounced in patients 
with higher UPDRS scores at baseline, the disease form 
with motor fluctuations and when more invasive 
procedures were undertaken. The observed 
improvements were distributed similarly during a 6-month 
period [30]. 
The expectation of improvement triggered by the 
administration of placebo produces the release of 
dopamine in the striatum, as shown by positron emission 
tomography using raclopride, and this supplemental 
dopamine leads to the alleviation of motor symptoms in 
Parkinson's disease [25,31].  
It was questioned in one study if the price of 
parkinsonism improvement when using placebo is the 
worsening of dyskinesia, as dyskinesia itself is considered 
to be generated by an excess of dopamine. However, the 
results contradicted this hypothesis: fewer patients 
showed placebo-related dyskinesia exacerbation 
compared with the alleviation and there was a lack of 
correlation between the changes in parkinsonism and 
changes in dyskinesia. These results were explained by 
the complexity of mechanisms underlying dyskinesia, as it 
is not a simple hyperdopaminergic state, but it is also due 
to receptor sensitization and pulsatile activity of 
dopamine. Moreover, other neurochemical mechanisms 
are thought to mediate the improvements of dyskinesia 
seen with placebo administration, such as glutamatergic, 
GABAergic, α2 adrenergic, serotonergic 5HT1A and 5HT2A, 
opioid, histamine H3, adenosine A2A receptors, the 
monoamine transport and cannabinoid CB1 receptors 
systems. The placebo effects in both parkinsonism and 
dyskinesia seem to be mediated by the alteration of 
NMDA receptor complex, which is involved in the 
expectation and reward mechanisms [32].   
One study investigated the quality of life (QoL) 
during one year of double-blind follow-up in patients with 
advanced Parkinson’s disease who received either 
transplantation of human embryonic dopamine neurons or 
sham surgery. QoL was assessed as a composite index 
of several scales commonly used in Parkinson's disease, 
including Unified Parkinson's Disease Rating Scale 
(UPDRS) and Parkinson's Disease Stress Scale, as well 
as more general scales that evaluated the physical, 
emotional and social functioning. It was discovered that 
both groups had a statistically significant improvement in 
physical functioning over the one-year period of follow-up, 
with no significant differences in the overall QoL in the 
initial phase of the study.  This study revealed a strong 
placebo response in Parkinson's disease, thought to be 
elicited by the extreme nature of the placebo used (brain 
surgery) and by the fact that no clues regarding the actual 
treatment could be perceived neither by the patients or 
the medical staff during the follow-up period [33]. The 
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placebo effect has also been investigated in parkinsonian 
patients who had been implanted electrodes for deep 
brain stimulation (DBS); the hand movement was faster 
when patients received a positive influence with the use of 
a placebo procedure [34]. Another study investigated the 
activity of single neurons in the subthalamic nucleus in 
patients who had been implanted with electrodes for DBS; 
the placebo-responders displayed a significant decrease 
of neuronal firing in the subthalamic nucleus during 
clinical improvement, which was reported by both the 
patient and the doctor [11]. 
The demographic information regarding the 
placebo effect in Parkinson's disease was obtained by an 
extensive search of the articles on this topic, published 
from 1969 to 1996 and listed in the Parkinson Study 
Group database for Deprenyl & Tocopherol Antioxidative 
Therapy of Parkinsonism (DATATOP). The survey 
concluded that the placebo effect did occur in Parkinson's 
disease, and it was not influenced by age, sex, religion, 
educational level or duration of the disease [35]. 
Neuropathic pain 
A review of fourteen studies that investigated 
gabapentin versus placebo in various types of 
neuropathic pain (post-herpetic neuralgia, diabetic 
neuropathy,  cancer related neuropathic pain, phantom 
limb pain, Guillain Barré syndrome, spinal cord injury 
pain) reported an average placebo response of 19% [36]. 
The placebo effect in neuropathic pain seems 
influenced by the intensity of pain at baseline and by the 
site characteristics, reported an analysis of three clinical 
trials that investigated lamotrigine versus placebo. The 
amplitude of placebo effect in reducing pain (on Pain 
Intensity Numerical Rating Scale) was greater for patients 
with high baseline pain scores and for patients belonging 
to sites with a faster recruitment rate [37]. 
Some studies reported a decrease in the 
function of opioid and dopaminergic systems in patients 
with chronic pain syndromes, which suggested a 
diminished neurobiological availability to respond to 
placebo treatments [16]. 
Headache 
One investigation that included 13 placebo-
controlled trials performed in children and teenagers with 
acute migraine, found a rate of pain relief ranging 
between 38% and 53% (a pooled placebo response of 
46%), and a rate of pain-free at 2 hours varying between 
17% and 26% (a pooled placebo response of 21%). 
These rates were inferior to those observed in North 
American clinical trials, leading to the conclusion of a wide 
variability of the placebo effect in pediatric migraine [38]. 
A recent synthesis of the results of several 
placebo-controlled clinical trials run in children and 
adolescents with migraine reported the following placebo 
response rates: 27.1% for pain free after 2 hours and 
56.9% for pain relief after 2 hours, in the parallel group 
trials [39]. 
A review of 11 clinical studies that investigated 
active treatments versus placebo in acute migraine 
revealed a wide range of placebo response rates, 
between 7-50% for pain decrease and 7-17% for pain 
cessation after 2 hours. The pooled placebo response 
rate was of 30% across these studies, with variations 
above and below this rate according to the primary 
endpoint, patient characteristics and design of the study 
[40]. 
In a systematic review of 11 placebo-controlled 
trials that investigated the treatment of acute migraine 
with analgesic drugs, an alleviation of pain was obtained 
in approximately 30% and pain cessation after 2h in 9% of 
the patients treated with placebo. One meta-analysis that 
included studies, which compared triptans with placebo, 
revealed an average rate of 30% placebo responders 
when the endpoint was pain relief and, 4-9% when the 
endpoint was the pain-free state. Another meta-analysis 
performed on 98 studies on migraine attacks gave a rate 
of 28.6% of patients who had pain improvement after 2 h, 
and 8.8% of patients who became free of pain after 
receiving placebo. The placebo response is lower in 
migraine prophylaxis: one meta-analysis, which included 
trials that compared propranolol to placebo, 14.3% of 
patients succeeded in attaining a reduction of > 50% in 
migraine frequency. A better response rate emerged from 
a meta-analysis of 32 studies that investigated migraine 
prophylaxis - the pooled placebo-response rate was of 
21% [41]. 
The rates of placebo response reported in 
clinical trials that investigated migraine were 
approximately equal to those observed in clinical trials 
performed in cluster headache patients. A review of six 
randomized, placebo-controlled studies, which 
investigated acute cluster headache, showed a rate of 
placebo responders ranging between 7% and 42%, for 
the endpoint represented by complete remission or mild 
headache. As for the prophylaxis of cluster headache, 
placebo was found to be effective in 14% to 43% of 
patients, based on the results of other two clinical trials 
[42]. 
Multiple sclerosis 
In multiple sclerosis clinical trials it is particularly 
difficult to separate the placebo effect from the natural 
history of the disease, as many cases have an 
unpredictable remission-relapsing pattern. Even if the 
exact cause of the phenomenon has not been 
established, several studies investigating interferon β-1a 
proved that a decrease in the number of lesions seen on 
the MRI scan, also occurred in the placebo groups [6]. 
 Epilepsy 
A recently published meta-analysis, which 
included 54 studies, that investigated antiepileptic drugs 
versus placebo in more than 11 000 adults and children 
with refractory epilepsy, emphasized the small difference 
in effectiveness between antiepileptic drugs and placebo. 
The weighted pooled-risk difference for a 50% decrease 
of seizure frequency in the whole sample of adults and 
children was of 6% and 21%, respectively. In the same 
publication, a parallelism was made with the results of a 
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previous meta-analysis on the same topic, which gave a 
rate of 0-2% for placebo in seizure-free patients [43]. 
An overview included a total of 28 clinical studies 
that investigated the effectiveness of several antiepileptic 
drugs (gabapentin, lamotrigine, tiagabine, topiramate, 
vigabatrin, and zonisamide) versus placebo as a 
treatment of refractory partial epilepsy. In the placebo 
arms, a response (defined as a reduction of seizure 
frequency of at least 50%) was obtained in 0-18% of the 
patients [44]. 
A recent meta-analysis that included 27 clinical 
trials which investigated antiepileptic drugs versus 
placebo in adults with focal drug-resistant epilepsy 
showed a pooled placebo response of 12.5% [45].  
Another meta-analysis that included 32 studies 
about drug-resistant partial epilepsy (investigating 
gabapentin, levetiracetam, lamotrigine, oxacarbazepine 
and topiramate versus placebo) concluded that the 
average placebo response rates were of 19% in children 
and 9.9% in adults. This responder rate, which was 1.9 
times higher in children than in adults, was stable across 
all antiepileptic drug trials. The reason for a better 
response to placebo in children is unclear; it may be due 
to a placebo effect by proxy, as the parents are those who 
report the outcome. However, since the studies did not 
include non-interventional groups, it cannot be estimated 
how much of this effect is due to other factors besides 
placebo, like Hawthorne effect, regression to the mean or 
the natural history of the disease [46]. 
One review of meta-analyses of randomized, 
placebo-controlled trials of antiepileptic drugs versus 
placebo included in Cochrane Library led to the 
conclusion that 9.3-16.6% of patients in the placebo arm 
had a >50% reduction in seizure frequency. It has been 
estimated that this effect accounts for 20-50% of the 
effect produced by the active medications, indicating the 
need for a better delineation of the true efficacy of each 
antiepileptic drug [47]. 
 
Issues raised in randomized clinical trials 
(RCTs) and ethical aspects of using placebo 
In RCTs, the real biological effectiveness is 
estimated as being the difference between the benefits 
observed in the active substance group and the placebo 
group; this might be a very reductionist approach, as the 
outcome may fluctuate with a variety of factors, including 
the details given during the informed consent process. 
When patients are told to participate in a placebo-
controlled RCT, the chance of dropout due to 
ineffectiveness is bigger than in a comparison-controlled 
RCT, for the group that receives the same active 
medication.  
In order to isolate the true placebo effects in a 
clinical trial, some factors that may influence the outcome 
should be excluded: subject biases, "halo" effect, 
Hawthorne effect and natural history of the disease. The 
first confounder can be controlled by blinding the subjects, 
although this method is not invulnerable, because the 
adverse event profile might provide a clue regarding the 
true administered treatment [48]. However, the last factor 
remains a serious issue, as nowadays quite a few clinical 
trials have a non-treatment group to which the placebo 
group could be compared [6,16].  
Given the fact that the placebo effect is 
responsible for the variability of the results in RCTs , 
several methods have been proposed to minimize it. One 
of them is the exclusion the placebo responders during 
wash-in periods; this approach is somehow unethical, 
because it refuses the chance of active treatment to a 
whole category of patients, and raises questions about 
the generalization of the study results [6] .  
In order to scrutinize the patients' opinion about 
receiving placebo in a randomized controlled trial, a 
qualitative sub-study that consisted of using the patient 
questionnaires was incorporated in a larger RCT. At the 
end of the RCT, the answers provided by the patients who 
received placebo were analyzed and the following 
conclusions were drawn: the fear of receiving placebo 
instead of active treatment was constant; they did not 
describe their feelings as "expectation", but "hope" of 
improvement; the vast majority reported a degree of 
improvement, psychosocial or/and symptomatic; there 
was persistent concern that the improvement might have 
been due to the normal evolution of disease or placebo 
effects [49]. 
One survey performed by giving questionnaires 
to patients of primary care clinics showed that 59% of the 
patients are open to the idea of participating in a placebo-
controlled trial, in order to support the development of a 
new treatment and help other patients. The patients' 
understanding of the placebo effects was generally poor, 
with a tendency of underestimating its effectiveness [50].  
Ethical concerns have been raised regarding the 
use of deception in neuroscience, as being a common 
approach thought to secure the scientific validity of the 
results; more than that, there is a lack of transparency in 
the published papers about the use of deception. Even if 
a written informed consent is formally obtained, the 
subjects are not actually informed about either the 
placebo use, or the purpose of the research. The U.S. 
federal regulations allow "a consent procedure which 
does not include, or which alters, some or all of the 
elements of informed consent...or waives the requirement 
to obtain informed consent", when the risks for the 
patients are minimal and their welfare is not 
compromised, the research could not be performed 
otherwise and the debriefing procedure is used after the 
study [51]. 
The use of placebo in clinical trials is ethically 
acceptable only when the risks of not getting the active 
treatment are not very high for the patients. In order to 
balance the scientific and ethical needs and make the 
appropriate decisions, periodical reassessments of every 
particular disease, with its subtypes and stages, are 
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undertaken by expert committees. For instance, an 
international committee has recently evaluated the ethics 
of running placebo-controlled clinical trials in relapsing 
multiple sclerosis; it was decided that the trials were still 
ethically acceptable, only if the active treatments were 
refused, inefficient or unavailable [52]. 
The use of sham surgery for neurological 
disorders has also been debated, as a necessary 
approach for the establishment of  the scientific validity of 
new surgery procedures in clinical trials, but respecting 
the safety and well-being of the patients. In order to 
address the ethical requirements, several conditions for 
the inclusion of  patients in this type of trials, have been 
proposed: the goal of the study is to bring new information 
that is scientifically valuable, there are no solid 
alternatives to using placebo, the risk of placebo is below 
an acceptable research risk, and, the patients authorize 
the use of deception to blind the placebo arm [53]. 
Conclusions 
Since 1955, when Beecher reported a rate of 
approximately 30% of placebo-responders in studies on 
analgesic drugs, further steps have been taken in 
understanding the placebo effect. More experience 
earned with the placebo effect in clinical trials enabled 
individualization of its impact on different pathological 
conditions, and a wide range of placebo-response rates 
have been acknowledged.                                                  
One published article gives a range of 5-65% for 
the placebo-induced improvements, the rate varying 
according to the particular CNS disease and sample size 
investigated in that study [16]. 
Given the fact that testing in a randomized 
placebo-controlled trial represents a crucial stage in the 
development of a new drug, in almost all therapeutic 
areas, a better understanding of the placebo effect has 
become of uttermost importance nowadays. The general 
current recommendation is to minimize the placebo effect 
in clinical trials, and the simplest way of doing that is to 
avoid making suggestions to patients. Studying the 
placebo effect in neurological disorders might provide 
better clues to a deeper understanding of the 
mechanisms involved, as it has been demonstrated by 
using performant-imaging techniques in the last several 
years. The applicability of this research area can be 
extremely vast, not only in neurology, but also virtually, in 
all medical fields. 
The active drugs have been always preferred as 
a more potent and reliable therapy of a disease, however, 
their success is not absolutely guaranteed. More than 
that, there are still neurological disorders with limited 
treatment options. Using placebo in these cases, as a last 
resort, might represent a humanitarian decision, and 
should be tried. In general, the clinicians' tendency is to 
recommend enhancing placebo effect in common medical 
practice, as a benign and potentially effective part of the 
therapeutic process. 
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